These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2839115)

  • 1. [Evaluation of tumor markers in the management of small cell lung cancer].
    Ariyoshi Y
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):959-65. PubMed ID: 2839115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
    Schneider J; Philipp M; Salewski L; Velcovsky HG
    Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
    Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
    Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study].
    Emin Erbaycu A; Gunduz A; Batum O; Zeren Ucar Z; Tuksavul F; Zeki Guclu S
    Arch Bronconeumol; 2010 Jul; 46(7):364-9. PubMed ID: 20537457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of combined detection of tumor markers for the prediction of small cell and non-small cell lung cancer].
    Wu Y; Wu Y; Wang L; Qu L
    Wei Sheng Yan Jiu; 2000 Jul; 29(4):213-5. PubMed ID: 12520921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer].
    Yang J; Li R; Li A
    Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):216-8. PubMed ID: 11778234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
    Bonner JA; Sloan JA; Rowland KM; Klee GG; Kugler JW; Mailliard JA; Wiesenfeld M; Krook JE; Maksymiuk AW; Shaw EG; Marks RS; Perez EA
    Clin Cancer Res; 2000 Feb; 6(2):597-601. PubMed ID: 10690544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC.
    Ebert W; Muley T; Trainer C; Dienemann H; Drings P
    Anticancer Res; 2002; 22(2B):1083-9. PubMed ID: 12168905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The diagnostic values of CA242 combining other tumor markers for lung cancer].
    Zhang S; Ma Y; Yang X
    Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):271-3. PubMed ID: 11775851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of the cut-off value of serum neuron-specific enolase in differentiating small cell lung cancer from non-small cell lung cancer].
    Wei T; Luo RC; Zuo Q; Zhang JY; Miao JX; Lu HF
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):858-9. PubMed ID: 16793621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cut-off levels of NSE to differentiate SCLC from NSCLC.
    Satoh H; Ishikawa H; Kurishima K; Yamashita YT; Ohtsuka M; Sekizawa K
    Oncol Rep; 2002; 9(3):581-3. PubMed ID: 11956631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
    Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H
    Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
    Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
    Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
    Pan QR; Zhang X; Xu ZF; Zheng S
    Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The prognostic value of serum neuron specific enolase detection in small cell lung cancer].
    Jin B; Zhao L; Zhou C
    Zhonghua Jie He He Hu Xi Za Zhi; 2001 Dec; 24(12):722-4. PubMed ID: 11930699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients.
    Shimizu M; Kondo M; Ito Y; Kume H; Suzuki R; Yamaki K
    Cancer Detect Prev; 2005; 29(2):175-80. PubMed ID: 15829378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ProGRP: a new biomarker for small cell lung cancer.
    Molina R; Filella X; Augé JM
    Clin Biochem; 2004 Jul; 37(7):505-11. PubMed ID: 15234231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.